2
Clinical Trials associated with TYF-IL-2Rg gene-modified autologous stem cells(Shenzhen Geno-Immune Medical Institute)Gene Therapy for X-linked Severe Combined Immunodeficiency (SCID-X1) Via Direct Intravenous Injection of Lentiviral Vector (Ivlv-X1)
This is a Phase I/II gene therapy trial treating X-linked severe combined immunodeficiency (SCID-X1) using a self-inactivating lentiviral vector (ivlv-X1) to functionally correct the genetic defect. The primary objectives are to evaluate the safety and efficacy of the direct intravenous lentiviral gene transfer protocol.
Lentiviral Gene Therapy for Chronic Granulomatous Disease (CGD)
This is a Phase I/II clinical trial of gene therapy for treating Chronic Granulomatous Disease using a high-safety, high-efficiency, self-inactivating lentiviral vector TYF to functionally correct the defective gene. The objectives are to evaluate the safety and efficacy of the TYF-CGD gene transfer clinical protocol.
100 Clinical Results associated with TYF-IL-2Rg gene-modified autologous stem cells(Shenzhen Geno-Immune Medical Institute)
100 Translational Medicine associated with TYF-IL-2Rg gene-modified autologous stem cells(Shenzhen Geno-Immune Medical Institute)
100 Patents (Medical) associated with TYF-IL-2Rg gene-modified autologous stem cells(Shenzhen Geno-Immune Medical Institute)
100 Deals associated with TYF-IL-2Rg gene-modified autologous stem cells(Shenzhen Geno-Immune Medical Institute)